AKBA Akebia Therapeutics, Inc.

CIK 0001517022 29 ready 8-Ks latest May 7, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 29

Latest filing May 7, 2026, 7:59 PM ET

Top materiality 0.85

Event mix earnings ×10 · other_material ×10 · leadership ×3

Sentiment 9 pos · 2 neg · 18 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for AKBA

Highest-materiality recent filing

Akebia abandons Vafseo broad label pursuit for non-dialysis CKD after FDA alignment failure

October 28, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 7.01 item 8.01 item 9.01

Akebia will not initiate the VALOR trial for vadadustat in late-stage CKD not on dialysis after FDA feedback.
FDA indicated the trial would require significantly more patients and meaningfully more time and cost.

Read filing →

May 7, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Akebia posts Q1 net loss of $9.1M; Vafseo revenue rises to $15.8M, patients up 60%

Net loss of $9.1M in Q1 2026 vs net income of $6.1M in Q1 2025; total revenues $53.5M, down from $57.3M.
April 1, 2026, 7:59 PM ET leadership materiality 0.50 neutral item 9.01

Akebia appoints Philip Vickers to board, replacing retiring Steven Gilman

Steven Gilman resigned as Class I director effective April 1, 2026; retirement not due to any disagreement.
February 26, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Akebia Q4 net product revenue $54.3M, full-year 2025 up 49% YoY; Vafseo launch gains traction

Q4 total revenue $57.6M (FY2025 $236.2M); net loss narrowed to $12.2M Q4 and $5.3M full year.
January 30, 2026, 6:59 PM ET other material materiality 0.55 neutral item 1.01 item 2.03 item 5.02 item 9.01 ◈ Material Agreements

Akebia leases 43,474 sq ft in Waltham for HQ; amends CEO/CFO severance

Leases 28,518 sq ft office + 14,956 sq ft lab at 180 Third Ave, Waltham, MA; HQ relocation planned for Sept 2026.
January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 7.01 item 9.01

Akebia expects Q4 2025 Vafseo net revenue $5-6M; dosed first patient in praliciguat Phase 2

Vafseo Q4 net product revenue expected $5-6M (vs. underlying dosing demand $10.5-11.5M) due to $4.5-5M inventory adjustment at USRC.
December 1, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01 item 7.01 item 8.01 item 9.01

Akebia buys ADX-097 from Q32 Bio for $10M upfront (total up to $582M milestones); plans Phase 2 trials in 2026

Upfront $7M paid at closing, additional $3M due in 6 months; development milestones up to $94.5M and commercial milestones up to $487.5M, plus tiered royalties from low single to mid-teen %.
November 17, 2025, 6:59 PM ET other material materiality 0.50 neutral item 1.01

Akebia amends Medice license to supply vadadustat and grant manufacturing rights

Amendment #1 to License Agreement signed Nov 12, 2025 with MEDICE Arzneimittel Putter GmbH & Co. KG.
November 10, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Akebia Q3 net income $0.5M; Vafseo revenue $14.3M; DaVita pilot ongoing

Q3 total revenue $58.8M (up 57% YoY vs $37.4M); net income $0.5M vs net loss $20.0M in Q3 2024.
October 28, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 7.01 item 8.01 item 9.01

Akebia abandons Vafseo broad label pursuit for non-dialysis CKD after FDA alignment failure

Akebia will not initiate the VALOR trial for vadadustat in late-stage CKD not on dialysis after FDA feedback.
August 7, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Akebia Q2 2025 net income $0.2M vs loss; Vafseo rev $13.3M, DaVita pilot in 100+ clinics

Net income $0.2M (vs net loss of $8.6M in Q2 2024); total revenue $62.5M, up 43%.
June 13, 2025, 7:59 PM ET other materiality 0.40 neutral item 5.02 item 5.07 item 9.01

Akebia shareholders approve 18.9M share increase to 2023 Stock Incentive Plan

Shareholders approved amendment to 2023 Stock Incentive Plan to increase shares by 18,900,000 (102.75M for, 48.21M against).
May 8, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Akebia posts Q1 2025 net income of $6.1M; Vafseo launch generates $12.0M in net product rev

Total Q1 2025 net product revenues $55.8M, up 80% YoY; Vafseo contributed $12.0M in first quarter of U.S. launch.
March 20, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 7.01 item 8.01 item 9.01

Akebia prices 25M-share public offering at $2.00/share, expects $46.5M net proceeds

Underwritten public offering of 25M shares at $2.00/share; gross proceeds $50M.
March 13, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Akebia Q4 net loss $22.8M; expects Vafseo Q1 2025 revenue ~$10-11M

Total revenues Q4 $46.5M, down 17% YoY; Auryxia net revenue $44.4M vs $53.2M.
February 7, 2025, 6:59 PM ET debt materiality 0.55 neutral item 1.01 item 2.03 item 3.02

Akebia draws $9.3M net from extended loan tranche; issues warrant for 1.15M shares

Extended Tranche C expiry from Dec 31, 2024 to Feb 3, 2025; interest accrues from Dec 31, 2024.
January 13, 2025, 6:59 PM ET other material materiality 0.65 neutral item 7.01 item 8.01 item 9.01

Akebia guides cash runway of at least two years, funding Vafseo launch and pipeline

Expects existing cash and cash from ops to fund current plan for at least two years.
November 7, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Akebia Q3 2024 net loss $20M; Vafseo launch on track for Jan 2025 with 60% dialysis patient coverage

Total revenues $37.4M in Q3 2024 vs $42.0M in Q3 2023, driven by Auryxia volume decline.
October 22, 2024, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Akebia signs multi-year supply agreement with leading dialysis org for Vafseo access

Contract with a leading kidney care provider serving >200,000 patients at thousands of U.S. dialysis centers.
October 16, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01

Akebia extends vadadustat supply agreement with STA through 2032

Amendment #1 to Supply Agreement with STA extended term to January 1, 2032.
August 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Akebia Q2 2024 net loss narrows to $8.6M; Vafseo launch on track for Jan 2025

Total revenues $43.6M (down 23% YoY); Auryxia net product rev $41.2M vs $42.2M in Q2 2023.
July 11, 2024, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 1.02

Akebia terminates Vafseo license with CSL Vifor, sets royalty payments and buy-down option

License agreement terminated immediately for business reasons; Akebia regains full U.S. marketing rights for Vafseo.
June 24, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change

Akebia Therapeutics appoints Erik Ostrowski as CFO and Chief Business Officer

Erik Ostrowski appointed Senior VP, CFO, Chief Business Officer and Treasurer, effective June 24, 2024.
June 10, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Akebia Therapeutics shareholders reject proposal to increase share reserve by 9.8M shares

Three Class I directors elected: Ronald E. Frieson, Steven C. Gilman, Ph.D., Cynthia Smith.
May 9, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Akebia Q1 net loss narrows to $18M; Vafseo FDA approved, launch set for Jan 2025

Total revenues $32.6M (Q1 2024) vs $40.0M (Q1 2023); Auryxia net product revenues $31.0M vs $34.7M.
April 23, 2024, 7:59 PM ET debt materiality 0.30 neutral item 2.03 ◈ Debt Financings

Akebia draws $8.0M Tranche B from Kreos loan facility; $10.0M Tranche C still available

Akebia drew $8.0M Tranche B loan on April 17, 2024, netting $7.5M after debt issuance costs and fees.
April 16, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01 ◈ Material Agreements

Akebia extends vadadustat supply agreement with STA to 2029

Amendment #2 extends Supply Agreement term to April 2, 2029 (five additional years).
March 28, 2024, 7:59 PM ET regulatory materiality 0.85 positive item 7.01 item 8.01 item 9.01

Akebia Therapeutics receives FDA approval for Vafseo (vadadustat) for dialysis patients

FDA approved Vafseo for anemia due to CKD in adults on dialysis ≥3 months; boxed warning for thrombosis risks.
March 15, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×2

Akebia CFO Ellen Snow to depart March 22; CEO John Butler named interim principal financial officer

CFO Ellen Snow and company mutually agree on transition; effective March 22, 2024.
March 14, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Akebia reports Q4 2023 net income $0.6M, Auryxia $53.2M; vadadustat PDUFA Mar 27

Net income of $0.6M in Q4 2023 vs net loss $6.1M a year ago; full-year net income $51.9M vs loss $94.2M in 2022.

Executive changes

Appointed

Erik Ostrowski

Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer

AKBA · Akebia Therapeutics, Inc.

Effective: 2024-06-24
Filed: June 24, 2024, 7:59 PM ET

On June 24, 2024, Akebia Therapeutics, Inc. (the “Company”) announced the appointment of Erik Ostrowski as the Company’s Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer, effective June 24, 2024

Appointed (interim)

John Butler

interim principal financial officer

AKBA · Akebia Therapeutics, Inc.

Effective: 2024-03-22
Filed: March 15, 2024, 7:59 PM ET

John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer from the Transition Date.

Departed

Ellen Snow

Senior Vice President, Chief Financial Officer and Treasurer

AKBA · Akebia Therapeutics, Inc.

Effective: 2024-03-22
Successor: John Butler
Filed: March 15, 2024, 7:59 PM ET

On March 15, 2024, Akebia Therapeutics, Inc. (the “Company”) and Ellen Snow mutually agreed that she would transition from her role as the Company’s Senior Vice President, Chief Financial Officer and Treasurer, effective March 22, 2024 (the “Transition Date”).

Earnings & guidance

2026-Q1 EPS reported -$0.03 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

9 positive 2 negative 18 neutral

source · AKBA on sec.gov